Stoke Therapeutics

Stoke Therapeutics is a clinical-stage biotechnology company focused on RNA medicine to restore protein expression in severe genetic diseases. Its lead program is zorevunersen for Dravet syndrome, and the company has generated revenue primarily from collaboration and licensing agreements, including its partnership with Biogen.

Relationship details are part of the Pro plan.